Human resistin compositions and methods of treating tlr4-mediated disease and infection
AssigneeThe Regents of the University of California
InventorsMeera G. NAIR, Jessica JANG, Gang CHEN
Life of this patent
Estimating the term…
Abstract
Compositions and methods for treating, mitigating, or preventing a Toll-like receptor (4) (TLR4)-mediated infection or disease in a host cell or a subject include administration of a resistin protein composition selected from full length resistin protein, a resistin protein fragment, or a fusion protein of resistin and an immunoglobulin G protein to the host cell or the subject having or likely to be exposed to a TLR4-mediated infection or disease.
Claims19
A method of treating a Toll-like receptor 4 (TLR4)-mediated infection or disease in a host cell or in a subject having the TLR4-mediated infection or disease, the method comprising:
- administering to the host cell or the subject an effective amount of a composition comprising a full length resistin protein, a resistin protein fragment, a fusion protein comprising a resistin protein or a fragment thereof and an immunoglobulin G protein, a fusion protein of an N-terminal or C-terminal resistin protein fragment and an immunoglobulin G (IgG) protein, homologs thereof, a derivative thereof, or a salt thereof.
A composition comprising a fragment of the full-length resistin protein, the fragment comprising any consecutive 84 amino acids of the human resistin protein hRetn (SEQ ID NO:
- 1) or homologs thereof.
A composition comprising a fusion protein of human resistin protein SEQ ID NO:
- 1 or homologs thereof and a fragment crystallizable (Fc) region of the IgG protein (Fc IgG) having an amino acid sequence of SEQ ID NO:
- 5.
Dependencies are inferred from the claim text.